Ozempic vs. Wegovy: Same Drug, Different Price — What You Need to Know

Prices verified May 22, 2026 · Updated for 2026

Same molecule, different labels

Ozempic and Wegovy are both manufactured by Novo Nordisk. Both contain semaglutide. Both are weekly injections that reduce appetite, slow stomach emptying, and produce weight loss. The critical differences are in dosing, FDA approval, and pricing—and those differences matter more than you'd think.

The key differences

Why Ozempic gets prescribed for weight loss

Despite Wegovy being the FDA-approved option for weight loss, many providers prescribe Ozempic off-label instead. Three reasons:

• Insurance coverage: Some insurance plans cover Ozempic (for diabetes) but not Wegovy (for weight loss). Providers may prescribe Ozempic off-label to navigate coverage gaps.
• Supply: During the 2023–2024 semaglutide shortage, Ozempic was sometimes easier to find than Wegovy at specific doses.
• Lower list price: Ozempic's list price (~$935/mo) is lower than Wegovy's (~$1,349/mo), which matters for patients without coverage.

The problems with off-label Ozempic for weight loss

Using Ozempic off-label for weight loss isn't illegal, but it creates real issues:

• Insurance audits: If your insurer covers Ozempic for diabetes and discovers it's being used off-label for weight loss, they can deny future claims and pursue repayment.
• Dose ceiling: Ozempic maxes out at 2.0mg. Wegovy goes to 2.4mg (and higher-dose Wegovy HD at 7.2mg is in development). The additional 0.4mg produces measurably more weight loss.
• Shortage contribution: Off-label weight loss use of Ozempic contributes to shortages that affect diabetic patients who need it for blood sugar control.
• No weight loss trial data at Ozempic doses: The STEP trials tested semaglutide at 2.4mg (Wegovy dose), not 2.0mg (Ozempic's max). Citing "15% weight loss" when prescribing Ozempic is using data from a different dose.

When Ozempic is the right choice

Ozempic is the correct prescription when you have type 2 diabetes and want the metabolic and cardiovascular benefits of semaglutide. Weight loss is a welcome secondary benefit, not an off-label application.

If your provider has diagnosed type 2 diabetes and prescribed Ozempic, your insurance coverage will be more straightforward, and you're using the medication as intended.

When Wegovy is the right choice

Wegovy is the correct prescription when your primary goal is weight loss and you meet the FDA-approved criteria: BMI ≥30, or BMI ≥27 with at least one weight-related condition (hypertension, type 2 diabetes, high cholesterol, etc.).

In 2026, the Wegovy pill adds a new option: FDA-approved for weight loss, starting at $149/mo through NovoCare, with no injection required. For patients choosing between off-label Ozempic and on-label Wegovy, the pill may eliminate the primary advantage (cost) that drove off-label use in the first place.

The compounded alternative

For cash-pay patients, the Ozempic-vs-Wegovy question becomes largely moot. Compounded semaglutide uses the same active ingredient, is dosed at whatever level your provider prescribes (including 2.4mg+), and costs $99–$299/mo through verified telehealth providers. You're getting semaglutide without the brand-name labeling distinction.

The tradeoff: compounded medications are not FDA-approved and depend on pharmacy quality. Always verify your provider uses 503A or 503B licensed pharmacies.

Our verdict

Use the medication that matches your diagnosis. If you have type 2 diabetes, Ozempic is appropriate. If your goal is weight loss, Wegovy is the FDA-approved choice—now available as both injection and pill. For cash-pay patients without a strong preference for brand-name, compounded semaglutide through a verified provider offers the same molecule at a fraction of the cost.